Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

Bladder Cancer – Padcev Plus Keytruda in 1st Line

BACKGROUND

Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic bladder cancer.

However, toxicity is substantial, responses are rarely durable, and many locally advanced or metastatic patients are ineligible.

Padcev and Keytruda have each shown a survival benefit versus chemotherapy in Bladder Cancer, are not restricted by cisplatin eligibility, and warrant investigation as a first-line combination therapy in patients ineligible for cisplatin.

WHAT IS PADCEV?

Padcev, also called Enfortumab Vedotin, is an antibody-drug conjugate used for the treatment of bladder cancer.

The most common side effects include fatigue, peripheral neuropathy, decreased appetite, rash, alopecia (hair loss), nausea, altered taste, diarrhea, dry eye, pruritus (itching) and dry skin.

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

WHAT IS KEYTRUDA?

Keytruda, also called Pembrolizumab, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer.

Common side effects include fatigue, musculoskeletal pain, decreased appetite, itchy skin (pruritus), diarrhea, nausea, rash, fever (pyrexia), cough, difficulty breathing (dyspnea), constipation, pain, and abdominal pain.

It is a type of antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them.

It targets the PD-1 receptor of lymphocytes.

Keytruda was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies.

It is on the World Health Organization’s List of Essential Medicines.

METHODS

In this Phase 1b/2 study, first-line cisplatin-ineligible locally advanced or metastatic patients received Padcev 1.25 mg/kg (Days 1 and 8) and Keytruda 200 mg (Day 1) intravenously in 3-week cycles.

RESULTS

Forty-five patients received Padcev plus Keytruda. The most common treatment-related side effects were peripheral sensory neuropathy, fatigue and alopecia.

Twenty-nine patients had difficult side effects. The most common were increased lipase, maculopapular rash and fatigue.

One death was associated with the treatment.

73.3% of patient benefited from the treatment experiencing a decrease in lesions’ size. In these patients the median Survival was 25.6 months.

15.6% of patients had complete remission. In these patients the median Survival was 26.1 months.

CONCLUSIONS

Padcev plus Keytruda showed a manageable safety profile.

Most patients experienced tumor shrinkage.

The median Survival exceeded 2 years in a cisplatin-ineligible patient population make this a promising combination.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

Read more about bladder cancer >>

Bladder Cancer - Padcev Plus Keytruda in 1st Line
Bladder Cancer – Padcev Plus Keytruda in 1st Line

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics